# **Special Issue**

# Ovarian Cancer Progression: From Experimental Models to Clinical Applications

# Message from the Guest Editors

The combination of cytoreductive surgery and chemotherapy for ovarian cancer is initially successful in decreasing tumor volume; however, the management of recurrent and progressive disease remains a significant treatment challenge. Discerning the enormous complexity of disease progression, through efforts that integrate disease biology with high-throughput computation and image-guided approaches, will contribute to the development of new treatment strategies. This Special Issue will be a platform to present interdisciplinary views about ovarian cancer progression. We would like to invite leaders in the field of ovarian cancer cell biology, computational biology, clinical diagnosis, and management. Authors should discuss the latest advances in ovarian cancer models (tissue and mouse models) and computational (omics, artificial intelligence) and imaging approaches. We especially encourage translational studies that identify links between biology and clinical application. We encourage submitting both original research and review articles.

### **Guest Editors**

Dr. Marcin Iwanicki

Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ 07030, USA

Dr. Mikołaj Piotr Zaborowski

Department of Gynecology Obstetrics and Gynecologic Oncology, Poznan University of Medical Sciences, Poznań, Poland

# Deadline for manuscript submissions

closed (20 February 2023)



# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/78119

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Author Benefits**

# **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

